Francisco J Pasquel

2 months ago | healio.com | Michael Monostra |Richard Smith |Francisco J Pasquel

Key takeaways: Use of the Omnipod 5 led to an HbA1c reduction of 0.8 percentage points at 13 weeks for adults with type 2 diabetes. FDA cleared the device for use in adults with type 2 diabetes in August. Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

2 months ago | jamanetwork.com | Francisco J Pasquel |Georgia Davis |David Huffman |Anne Peters

Key PointsQuestion  Is automated insulin delivery (AID) safe and effective for use in adults with type 2 diabetes who are being treated with insulin with or without other glucose-lowering medications? Findings  In this nonrandomized clinical trial including 305 adults with type 2 diabetes, there was a significant decrease in hemoglobin A1c (HbA1c) levels from 8.2% to 7.4% after 13 weeks of AID use, representing a 0.8–percentage point reduction.